Discover Algeria | About us | Press area | Contact | ||||||||
|
Les derniers textes juridiques
View more
Les interviews By AlgeriaInvest
Newsletter
NEW OPPORTUNITIES
NEW NEWS
September 26, 2024 | 3 months ago
Sharing
This launch marks an important milestone in Algeria's efforts to achieve self-sufficiency in pharmaceutical production and improve the care of diabetic patients.
The Biocare Group is ensuring that this new production will be carried out entirely in Algeria, without recourse to imports, unlike previous practices where insulin was imported and then packaged in Algeria. This initiative is part of the government's efforts to strengthen the national pharmaceutical industry and ensure greater autonomy for medicines, particularly for the treatment of diabetes, a disease that affects a large part of the population.
The "Made in Algeria" insulin will be officially presented at a meeting in Algiers on Friday. This event will bring together health experts and doctors specialising in diabetes from the wilayas in the centre of the country. Representatives from the Ministries of Health and the Pharmaceutical Industry will also be present to provide health professionals with details and explanations about this product.
Algerian insulin pen: 2 different versions available
Marketing will begin in the coming days from Biocare's production facility in Oued Smar, Algiers, with gradual distribution through the country's pharmacies. The insulin will be available in two formulas: "Bio Rapid" for rapid glycaemic control and "Bio Mix", a mixture of rapid and slow insulin designed to stabilize blood glucose levels overnight.
Algeria has recently begun exporting its insulin pens to neighbouring countries such as Libya. The progress of the Algerian pharmaceutical industry does not stop there, as the national insulin production has influenced other more distant regions, such as Saudi Arabia, which recently received nearly 2.5 million insulin pens manufactured in Algeria.
Sharing